JPMorgan Chase & Co. Decreases Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

JPMorgan Chase & Co. decreased its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 70.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,680 shares of the biotechnology company's stock after selling 39,519 shares during the quarter. JPMorgan Chase & Co.'s holdings in Capricor Therapeutics were worth $230,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CAPR. Corebridge Financial Inc. boosted its position in shares of Capricor Therapeutics by 32.2% during the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock valued at $251,000 after purchasing an additional 4,434 shares in the last quarter. Vanguard Group Inc. lifted its stake in Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after buying an additional 700,243 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $91,000. Teacher Retirement System of Texas bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at $141,000. Finally, Intech Investment Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter valued at $228,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Trading Down 5.0 %

Shares of CAPR traded down $0.35 on Friday, reaching $6.62. The company's stock had a trading volume of 1,131,123 shares, compared to its average volume of 1,435,229. The stock has a market capitalization of $302.38 million, a PE ratio of -6.25 and a beta of 0.85. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a fifty day moving average of $11.31 and a 200-day moving average of $14.33.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. As a group, equities analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CAPR has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.